Navigation Links
Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
Date:5/14/2009

ROCKVILLE, Md., May 14 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it will present posters on its newly approved atypical antipsychotic, Fanapt(TM) (iloperidone), at the 162nd American Psychiatric Association (APA) annual meeting in San Francisco, California. Fanapt(TM) is indicated for the acute treatment of schizophrenia in adults. Vanda will also present two posters on tasimelteon at APA. Tasimelteon is an investigational compound in development for the treatment of circadian rhythm sleep disorders, including transient insomnia caused by jet lag.

The following two posters discussing data from Fanapt(TM) clinical trials will be presented at scientific poster sessions on Monday, May 18 from 9:00 am to 10:30 am. 

    NR1-033       Efficacy of Iloperidone is Comparable to Risperidone in
    Analyses of a Placebo- and Risperidone-Controlled Clinical Trial for
    Schizophrenia.

    NR1-026       The Comparative Efficacy of Iloperidone and Haloperidol
    Across Four Short-Term Controlled Trials.

The following four posters discussing genetic and genomic studies in schizophrenia will be presented at scientific poster sessions on Monday, May 18 from 9:00 am to 10:30 am (NR1-095, NR1-058, NR1-092) and on Wednesday, May 20 from 3:00 pm to 5:00 pm (NR7-009). 

    NR1-095       Effect of 6 genetic markers associated with iloperidone
    efficacy on long term clinical outcome of patients who switch to
    iloperidone.

    NR1-058       Effect of polymorphisms in the dopamine receptor 2 gene on
    iloperidone efficacy for the treatment of patients with schizophrenia.

    NR7-009       Common effect of antipsychotics on biosynthesis and
    regulation of fatty acids and cholesterol supports a role of lipid
    homeostasis 
'/>"/>
SOURCE  Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports First Quarter 2009 Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...Gabon, December 2 , - "Bo...m and Heritage" , Coinciding with the Int...,Gabonese Republic is hosting an international con...guarding biological resources in Africa. The,confe...ders, ministers,scientific experts, private compa...
(Date:12/2/2009)...Mass., Dec. 2 TechConnect World, a...y development and product integration in cleantech...er 11th deadline for technology abstracts and busi...chConnect World, in association with the Nano Scie... Technology and Sustainable Industries Organizatio...
(Date:12/2/2009)...Dec. 2 S*BIO Pte Ltd today announc...itor, SB1518, at The American Society of Hematolog...s. ,, Data will be presented on the clinical re...1518 detailing its safety, tolerability and pharma...levels ranging from 100 to 600 mg. These doses wer...
(Date:12/2/2009)...hina, Dec. 2 /PRNewswire-Asia/ -- Simcere Pharmace... SCR ), a leading pharmaceutical company,specializ...ng of branded,generic and proprietary pharmaceutic...s have been included in China,s National Drug Reim...,s Ministry of Human Resources and Social,Security...
Breaking Biology Technology:Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 2Simcere Announces 105 Drugs Included in China's National Drug Reimbursement List 3
..., Human plasma and serum represents an impo...iagnosis. However, the wide dynamic range in prote...nge in the development of diagnostic assays for ,...roteins in the presence of high , abundan... to remove 99% , of the diagnostically un...
...acy Worzella and Brad Larson , Promega Co... , Application Note 139 ... , Multiplexing homogeneous cell-based a...ers from a single sample well , Monitoring... Assay miniaturization up to 1536-well format...
...rjan Orban 1 , Francois Degorce 2 and Jean-Luc ,...many; 2 Cisbio international, France , ... , Rev. 12/2005 , ...pathway investigation under HTS conditions , ...r with the HTRF , IP-One assay in terms...
Other Biology Technology:Protein Depletion for Plasma and Serum Proteomic Analysis 2Protein Depletion for Plasma and Serum Proteomic Analysis 3Protein Depletion for Plasma and Serum Proteomic Analysis 4Protein Depletion for Plasma and Serum Proteomic Analysis 5Protein Depletion for Plasma and Serum Proteomic Analysis 6Protein Depletion for Plasma and Serum Proteomic Analysis 7Protein Depletion for Plasma and Serum Proteomic Analysis 8Protein Depletion for Plasma and Serum Proteomic Analysis 9Protein Depletion for Plasma and Serum Proteomic Analysis 10Protein Depletion for Plasma and Serum Proteomic Analysis 11Protein Depletion for Plasma and Serum Proteomic Analysis 12Protein Depletion for Plasma and Serum Proteomic Analysis 13Protein Depletion for Plasma and Serum Proteomic Analysis 14Protein Depletion for Plasma and Serum Proteomic Analysis 15Protein Depletion for Plasma and Serum Proteomic Analysis 16Protein Depletion for Plasma and Serum Proteomic Analysis 17Protein Depletion for Plasma and Serum Proteomic Analysis 18Protein Depletion for Plasma and Serum Proteomic Analysis 19Protein Depletion for Plasma and Serum Proteomic Analysis 20Protein Depletion for Plasma and Serum Proteomic Analysis 21Protein Depletion for Plasma and Serum Proteomic Analysis 22Protein Depletion for Plasma and Serum Proteomic Analysis 23Protein Depletion for Plasma and Serum Proteomic Analysis 24Protein Depletion for Plasma and Serum Proteomic Analysis 25Protein Depletion for Plasma and Serum Proteomic Analysis 26Protein Depletion for Plasma and Serum Proteomic Analysis 27Protein Depletion for Plasma and Serum Proteomic Analysis 28Protein Depletion for Plasma and Serum Proteomic Analysis 29Protein Depletion for Plasma and Serum Proteomic Analysis 30Protein Depletion for Plasma and Serum Proteomic Analysis 31Protein Depletion for Plasma and Serum Proteomic Analysis 32Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar 2Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar 3Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar 4Promegas Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar 5
(Date:12/3/2009)...a personality change in warmer water, according to...hange may make some species more aggressive. , E... Australia,s Great Barrier Reef have shown for the...ently timid, or consistently bold, and that these ...er temperatures rise. , A slight lift of just on...
(Date:12/3/2009)...it comes to investment in energy efficient technol...ces Research Council (EPSRC) Chief Executive Dave ...d engineering research has already brought us fuel...t more investment is needed to develop the capabil... carbon emission targets by 2020 and limit the imp...
(Date:12/2/2009)...turated Latino men have a more difficult time quit...to U.S. culture, but acculturation has no affect o...se findings are published in Cancer Epidemiology,...an Association for Cancer Research. The December i...ation affects smoking cessation differently for La...
Breaking Biology News(10 mins):Fish with attitude: Some like it hot 2Research is vital to a cleaner, greener, low carbon future 2Acculturation affects smoking cessation success among Latinos 2Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 1Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 2Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 3Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 4Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 5Resuscitation and Survival Rates from Out of Hospital Cardiac Arrest Nearly Double with Comprehensive Treatment Protocol 61476 6Survey Finds AARP Members Back Health Care Reform Legislation 61472 1Survey Finds AARP Members Back Health Care Reform Legislation 61472 2Gen Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts 14858 1Gen Probe Announces Webcast of Annual Briefing for Institutional Investors and Financial Analysts 14858 2
...he molecular machines that drive all life, also sh...he study, in the journal Structure , reveals that...y experienced a "big bang" of innovation. The acti...ned with each other or split apart to produce a ho...This explosion of new forms coincided with the rap...
...s animals of the Americas avoid competing for the ...ssible answer comes from a new study by a pair of .... Their large-scale analysis shows that it,s not j...s themselves that have been a driving force in the...ctors as whether species are active daytime or nig...
..., 2009)Attempts to treat critical limb ischemia in...elow-the-knee angioplasty are still thwarted by re...te of angioplasty or stenting), the need for repea...rosclerotic disease, leading to tissue death (gang...have been studying a potential solutionthe use of ...
Other Biology News:Study of protein structures reveals key events in evolutionary history 2American carnivores evolved to avoid each other, new study suggests 2Promising 3-year data: Saving limbs with drug-eluting stents 2Promising 3-year data: Saving limbs with drug-eluting stents 3
...ains 200 g of lyophilized peptide derived from the...ds 380-402; GLTPSAWEASSLRSSRHSGLSHF. This peptid...s EP1 receptor polyclonal antibody (Catalog No. 10...ibody to block protein-antibody complex formation ...
Goat Anti-Mouse Ig + IgM Antibody, FITC Conjugated from Cayman Chemical
Rabbit Anti-TRBP1 Polyclonal Antibody, Unconjugated from ProSci, Inc
Donor feline Serum - 100mL from GeneTex
Biology Products: